Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Seep, Jacob
SIRIUS-SLE 2, NCT05624749 / 2022-002690-29: Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus	Recruiting	3	280	Europe, US, RoW	ianalumab, VAY736, placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Systemic Lupus Erythematosus	01/27	01/29
NCT05363891: Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis	Recruiting	2	210	US	Natrunix, True Human IgG4 monoclonal antibody, Placebo	XBiotech, Inc.	Rheumatoid Arthritis	08/24	10/24